117 related articles for article (PubMed ID: 27460209)
1. Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitors.
Wang H; Lawson JD; Scorah N; Kamran R; Hixon MS; Atienza J; Dougan DR; Sabat M
Bioorg Med Chem Lett; 2016 Sep; 26(17):4334-9. PubMed ID: 27460209
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors.
Sabat M; Wang H; Scorah N; Lawson JD; Atienza J; Kamran R; Hixon MS; Dougan DR
Bioorg Med Chem Lett; 2017 May; 27(9):1955-1961. PubMed ID: 28359790
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
4. Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5).
Goldberg FW; Ward RA; Powell SJ; Debreczeni JE; Norman RA; Roberts NJ; Dishington AP; Gingell HJ; Wickson KF; Roberts AL
J Med Chem; 2009 Dec; 52(23):7901-5. PubMed ID: 19736928
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of novel 4-thiazolylimidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Amada H; Sekiguchi Y; Ono N; Matsunaga Y; Koami T; Asanuma H; Shiozawa F; Endo M; Ikeda A; Aoki M; Fujimoto N; Wada R; Sato M
Bioorg Med Chem Lett; 2012 Mar; 22(5):2024-9. PubMed ID: 22325945
[TBL] [Abstract][Full Text] [Related]
6. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors.
Gellibert F; Fouchet MH; Nguyen VL; Wang R; Krysa G; de Gouville AC; Huet S; Dodic N
Bioorg Med Chem Lett; 2009 Apr; 19(8):2277-81. PubMed ID: 19285388
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
[TBL] [Abstract][Full Text] [Related]
8. ALK5 kinase inhibitory activity and synthesis of 2,3,4-substituted 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles.
Řezníčková E; Tenora L; Pospíšilová P; Galeta J; Jorda R; Berka K; Majer P; Potáček M; Kryštof V
Eur J Med Chem; 2017 Feb; 127():632-642. PubMed ID: 28135685
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI).
Roth GJ; Heckel A; Brandl T; Grauert M; Hoerer S; Kley JT; Schnapp G; Baum P; Mennerich D; Schnapp A; Park JE
J Med Chem; 2010 Oct; 53(20):7287-95. PubMed ID: 20919678
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
11. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
[TBL] [Abstract][Full Text] [Related]
12. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
13. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors.
Gellibert F; Woolven J; Fouchet MH; Mathews N; Goodland H; Lovegrove V; Laroze A; Nguyen VL; Sautet S; Wang R; Janson C; Smith W; Krysa G; Boullay V; De Gouville AC; Huet S; Hartley D
J Med Chem; 2004 Aug; 47(18):4494-506. PubMed ID: 15317461
[TBL] [Abstract][Full Text] [Related]
14. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
15. Screening and identification of a novel class of TGF-β type 1 receptor kinase inhibitor.
Huynh QK; Wise SJ; Koch KA; Castonguay LA; Reid BG; Pagratis EE; Koditek D; Glascock CB; Pitts KR; Turner BA; Liu X; Hung M; Han B; Pagratis N
J Biomol Screen; 2011 Aug; 16(7):724-33. PubMed ID: 21521800
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia.
Amada H; Asanuma H; Koami T; Okada A; Endo M; Ueda Y; Naruse T; Ikeda A
Chem Pharm Bull (Tokyo); 2013; 61(3):286-91. PubMed ID: 23449197
[TBL] [Abstract][Full Text] [Related]
18. Pyrazinoindolone inhibitors of MAPKAP-K2.
Goldberg DR; Choi Y; Cogan D; Corson M; DeLeon R; Gao A; Gruenbaum L; Hao MH; Joseph D; Kashem MA; Miller C; Moss N; Netherton MR; Pargellis CP; Pelletier J; Sellati R; Skow D; Torcellini C; Tseng YC; Wang J; Wasti R; Werneburg B; Wu JP; Xiong Z
Bioorg Med Chem Lett; 2008 Feb; 18(3):938-41. PubMed ID: 18221871
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.
Boys ML; Bian F; Kramer JB; Chio CL; Ren XD; Chen H; Barrett SD; Sexton KE; Iula DM; Filzen GF; Nguyen MN; Angell P; Downs VL; Wang Z; Raheja N; Ellsworth EL; Fakhoury S; Bratton LD; Keller PR; Gowan R; Drummond EM; Maiti SN; Hena MA; Lu L; McConnell P; Knafels JD; Thanabal V; Sun F; Alessi D; McCarthy A; Zhang E; Finzel BC; Patel S; Ciotti SM; Eisma R; Payne NA; Gilbertsen RB; Kostlan CR; Pocalyko DJ; Lala DS
Bioorg Med Chem Lett; 2012 May; 22(10):3392-7. PubMed ID: 22542194
[TBL] [Abstract][Full Text] [Related]
20. Tgf-beta type I receptor (Alk5) kinase inhibitors in oncology.
Ling LE; Lee WC
Curr Pharm Biotechnol; 2011 Dec; 12(12):2190-202. PubMed ID: 21619541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
